Stock SUPN SUPERNUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Supernus Pharmaceuticals, Inc.

Equities

SUPN

US8684591089

Real-time Estimate Cboe BZX
Other stock markets
 10:27:51 2024-04-16 am EDT 		5-day change 1st Jan Change
29.81 USD -0.60% Intraday chart for Supernus Pharmaceuticals, Inc. -5.67% +3.42%
Apr. 08 Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready DJ
Apr. 08 Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready
DJ
Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket
MT
Supernus Pharmaceuticals, Inc. Announces a Regulatory Update for SPN-830
CI
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease
RE
Supernus Provides Regulatory Update for SPN-830
GL
Supernus Provides Regulatory Update for SPN-830
AQ
Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing
MT
Supernus Pharmaceuticals Insider Sold Shares Worth $436,573, According to a Recent SEC Filing
MT
Transcript : Supernus Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:35 PM
Supernus to Participate in Two Upcoming Investor Conferences
GL
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
GL
Piper Sandler Cuts Price Target on Supernus Pharmaceuticals to $41 From $45, Maintains Overweight Rating
MT
Supernus: Q4 Earnings Snapshot
AQ
Transcript : Supernus Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023
CI
Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024
CI
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Posts Q4 Revenue $164.3M, vs. Street Est of $155M
MT
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
GL
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SUPN Stock
  4. News Supernus Pharmaceuticals, Inc.